News

ChemPartner announced today the appointment of Yinfei Yin, Ph.D. as vice president of and head of the biology and pharmacology department at Shanghai ChemPartner. Dr. Yin brings a wealth of experience and expertise to his new role, having established himself as a...

Shanghai, China (March 23, 2020) – Shanghai ChemPartner announced today the appointment of Cheng-Chi Chao, Ph.D. as Vice President and Head of Immunotherapy and Inflammation. Dr. Chao has over 20 years of experience in drug development and extensive expertise in the...

Shanghai, China (June 9, 2020) – Shanghai ChemPartner announced the additional investments the company is making into its biologics business unit to further its capabilities and capacity in biologics discovery through development and manufacturing. “ChemPartner has...

Shanghai, China (May 12, 2020) – Shanghai ChemPartner announced they have entered into a non-exclusive agreement with the Mount Sinai Health System (Mount Sinai) to assist in a trial production run of a component of the Mount Sinai COVID-19 serological assay that...

SAN FRANCISCO, Calif. and SHANGHAI, China. (April 15, 2020) – In a new collaboration, Chempartner Corporation (ChemPartner), the US arm of a leading pre-clinical contract research and development organization (CRO), is partnering with scientists at Gladstone...

Shanghai, China (March 17, 2020) – Shanghai ChemPartner announced the opening of a new, state-of-the-art, 24,000 m2 laboratory facility in the Zhangjiang Hi-Tech Park in Shanghai, China. The building, operating as ChemPartner’s new Global Operation Center, houses...